ABSTRACT
Background To identify the CT features of anterior mediastinal thymoma and lymphoma and evaluate CT findings that may help in suggesting specific diagnosis among these tumors
Method A total of fifty-eight chest CT scan studies with pathological diagnosis of thymoma [n = 30] and lymphoma [n =28] were retrospectively reviewed by two radiologists who were blind to the pathological results. The CT features showing cyst and calcification within the lesion, contrast enhancement, relation with pleura and adjacent vessels, bone invasion and lymph node enlargement were evaluated
Results In lymphoma [67.9%], the presence of associated mediastinal lymphadenopathy was significantly compared to thymoma. [P < 0.05]. The presence of calcification within the lesion was significantly found in thymoma than the lymphoma [p <0.05]. The presence of adjacent vessels relationship within the lesion was higher in lymphoma than the thymoma. [p <0.05] The remaining CT findings showed no significant difference among these diseases [p > 0.05]
Conclusion In conclusion age, lymph nodes involvement, calcification and relationship to adjacent vessels on CT scan will be helpful to give specific diagnosis on anterior mediastinum lymphoma and thymoma
ABSTRACT
In this study, we investigated the pharmacokinetics parameters of SPIO-shRNA dual functional molecular probe and observed the main organ distribution by MRI in vivo. Eighteen New Zealand white rabbits were randomly divided into three groups and injected intravenously with different doses of SPIO-shRNA molecular probe, respectively. The blood samples were collected to analyze the pharmacokinetic parameters by measuring the iron content at 30 minutes before and after the injection. Twenty-four Kun Ming (KM) mice were randomly divided into 4 groups: the control group was injected intravenously with physiological saline 200 µL per mouse via the tail vein, the other 3 groups were injected intravenously with different doses of SPIO-shRNA molecular probe. MRI observation was performed in 24 hours, and the liver, spleen, kidney, brain and muscle were collected for iron quantification with Prussian blue staining to determine distribution of the SPIO-shRNA molecular probe in the main organ in vivo. Our results suggest that the molecular probe blood half-life is more than 3 hours. The data of MRI suggest the probe was distributed in liver and spleen, and the MRI signal was reduced with the increase in probe's doses (P < 0.05). The results of Prussian blue staining confirmed the results of MRI. Most of the probe could escape the phagocytosis of mononuclear phagocyte system. Our data provide the pharmacokinetic and distribution of SPIO-shRNA molecular probe in organs. Meanwhile, it suggests the choice of the time and dose of probe for MR imaging of tumor in vivo.